Find policies, billing codes, payers, states, and providers
CPT 0570U: i–STAT TBI Blood/Plasma Test for GFAP and UCH‑L1
CPT code 0570U is a Proprietary Laboratory Analyses (PLA) code that identifies the i–STAT TBI test from Abbott Point of Care, a blood/plasma assay measuring GFAP and UCH‑L1 biomarkers. The test yields individual biomarker values and an overall binary result (elevated or nonelevated) used to detect brain injury. Nationally, this code matters because it standardizes reporting for a single-manufacturer point-of-care diagnostic that can influence emergency department triage and imaging decisions.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical purpose and service setting, payer coverage considerations, and common billing modifiers tied to laboratory and point-of-care testing. The publication covers benchmark reporting where available, relevant policy developments affecting PLA codes, and clinical context about GFAP and UCH‑L1 use in acute brain injury evaluation.
This summary is intended to inform coding, billing, and policy stakeholders about the clinical role and billing identity of the i–STAT TBI assay under CPT code 0570U, and what to expect in payer coverage and administrative handling of this single-source diagnostic service.
Customize your policy alerts
Sign up for cpt 0570U policy alerts
Get alerted when payer policies referencing 0570U are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 0570U is a Proprietary Laboratory Analyses (PLA) code that applies only to a single, specific laboratory test: the i–STAT TBI from Abbott Point of Care. The test measures two brain-injury–associated proteins, glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl–terminal hydrolase L1 (UCH‑L1), in blood or plasma. Results for each biomarker are reported individually and are combined into an overall result of either elevated or nonelevated based on a predefined threshold.
Service type: Proprietary laboratory diagnostic test (PLA) for blood/plasma biomarker analysis.
Typical site of service: Point-of-care or clinical laboratory setting, including emergency department and hospital-based point-of-care testing environments where the i–STAT platform is used.
Data not available in the input.